ArticleBMC gastroenterology2025
Mesenteric fat proliferation on magnetic resonance enterography is a predictor of long-term disease complications in crohn's disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mesenteric Panniculitis in a Patient with Ulcerative Colitis in Remission on Vedolizumab Therapy: A Case Report and Literature Review.Journal of clinical medicine · 2026Review
- Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics.Frontiers in immunology · 2026Review
- The Utility of Mesenteric T1 Mapping on MR Enterography in Crohn's Disease: A Preliminary Study.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibrofatty proliferation of mesenteric fat is a common finding on magnetic resonance enterography (MRE) in Crohn's disease (CD) patients. Mesenteric fat may play a role in inflammation, fibrosis, and stricture formation, but its prognostic value in predicting complications remains unclear.
objectivesTo assess the association between mesenteric fat proliferation on MRE and the risk of hospital admissions and bowel surgery in CD patients.
methodsIn this retrospective single-center study, CD patients with available MRE data were followed for CD exacerbation-related hospitalizations or abdominal surgeries. An expert radiologist reviewed MRE for intestinal wall thickening, stricture, abscess formation, fibrofatty proliferation, and fat edema. Kaplan-Meier and Cox proportional hazards regression models were used to analyze associations between mesenteric fat and outcomes, adjusting for clinical and imaging characteristics.
resultsAmong 175 CD patients mesenteric fat proliferation and edema were noted in 52 (29.7%) and 15 (8.9%) patients, respectively. Other findings included wall thickening (46.9% mild, 29.1% moderate, 7.4% severe), stricture (14.3%), abscess (5.7%), and fistula (6.9%). During a mean follow-up of 95.2 months, 93 (51.3%) patients were hospitalized for CD-related reasons, and 47 (26.9%) underwent CD-related abdominal surgery. Mesenteric fat proliferation was strongly associated with hospitalizations and surgery (p < 0.0001 for both). Multivariable analysis confirmed these associations with adjusted hazard ratios (aHR) of 3.45 (95%CI 1.66-7.19) 3.74 (95%CI) for surgery and 1.92 (95%CI 1.16-3.15) 2.03 (95%CI) for hospitalizations. Fat edema was linked to surgery and hospitalization but lost significance in multivariable analysis.
conclusionsMesenteric fat proliferation on MRE is independently associated with increased risk of hospitalizations and surgery in CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.